Research shows that early stomach cancer develops differently depending on whether it stems from H. pylori bacterial infection or autoimmune gastritis. According to Gram Research analysis of 130 patients, autoimmune gastritis patients had much lower pepsinogen I levels (11.5 vs. 66.5 micrograms per liter) and vitamin B12 (269 vs. 538 nanograms per liter), and their cancers appeared as flat lesions rather than depressed ones. Autoimmune patients also had a higher rate of aggressive signet ring cell carcinoma (30.8% vs. 7.0%), suggesting doctors should use different screening strategies for each inflammation type.
Researchers compared how early stomach cancer develops in patients with two different types of chronic stomach inflammation. According to Gram Research analysis, patients with autoimmune gastritis (a condition where the body attacks its own stomach lining) showed different warning signs and cancer patterns compared to those with H. pylori bacterial infection. The study of 130 patients found that these two conditions require different monitoring strategies to catch cancer early. Understanding these differences could help doctors screen and treat patients more effectively based on which type of inflammation they have.
Key Statistics
A 2025 research study of 130 patients found that autoimmune gastritis patients had pepsinogen I levels of 11.5 micrograms per liter compared to 66.5 in H. pylori patients, indicating much less stomach acid production in autoimmune cases.
Among 130 early stomach cancer patients studied between 2022 and 2025, autoimmune gastritis patients showed signet ring cell carcinoma in 30.8% of cases versus only 7.0% in H. pylori patients, suggesting autoimmune inflammation may lead to more aggressive cancer types.
A 2025 analysis of 130 patients revealed that autoimmune gastritis patients had vitamin B12 levels of 269 nanograms per liter compared to 538 in H. pylori patients, reflecting the nutritional deficiencies common in autoimmune stomach disease.
In a 2025 study of 130 patients with early stomach cancer, H. pylori-related gastritis showed extensive tissue damage with 38.8% at OLGA stage 3 and 15.0% at stage 4, compared to less severe damage in autoimmune gastritis patients.
The Quick Take
- What they studied: How early stomach cancer and precancerous changes look different depending on whether they develop from H. pylori bacterial infection or autoimmune gastritis (where your immune system attacks your stomach).
- Who participated: 130 patients treated at Beijing Hospital between January 2022 and February 2025 who had early stomach cancer or precancerous stomach lesions. The group included 106 patients with H. pylori-related inflammation and 24 with autoimmune gastritis. The autoimmune group had significantly more women (17 women vs. 7 men) compared to the H. pylori group (40 women vs. 66 men).
- Key finding: The two types of stomach inflammation produce early cancers with distinctly different appearances under the endoscope and different patterns of tissue damage. Autoimmune gastritis patients had much lower levels of pepsinogen I (11.5 vs. 66.5 micrograms per liter) and vitamin B12 (269 vs. 538 nanograms per liter) compared to H. pylori patients.
- What it means for you: If you have stomach inflammation, your doctor may need to use different screening approaches depending on whether it’s caused by H. pylori infection or autoimmune gastritis. This research suggests a one-size-fits-all monitoring strategy may miss important warning signs in autoimmune patients. Talk to your gastroenterologist about which type of inflammation you have and what screening schedule is right for you.
The Research Details
Researchers reviewed medical records and endoscopy findings from 130 patients who visited a major hospital in Beijing over three years. They divided patients into two groups based on the type of stomach inflammation they had: those with H. pylori bacterial infection (106 patients) and those with autoimmune gastritis (24 patients). For each patient, they recorded clinical information, what the stomach lining looked like during endoscopy (a camera procedure to view the stomach), tissue samples under a microscope, and how well a minimally invasive treatment called endoscopic submucosal dissection worked. They used standard statistical tests to compare the groups, checking for differences in blood markers, appearance of lesions, and tissue damage patterns.
Early stomach cancer is easier to treat when caught before it spreads deeply into the stomach wall. However, the warning signs and risk patterns may differ depending on what caused the initial inflammation. By identifying these differences, doctors can create targeted screening plans for each type of patient. This approach is more efficient than using the same strategy for everyone, which might miss cancers in autoimmune patients or over-screen H. pylori patients unnecessarily.
This study used a real-world patient population from a major hospital, which makes findings more applicable to actual clinical practice. The researchers used established classification systems (OLGA and OLGIM staging) that are internationally recognized for assessing stomach damage. The statistical methods were appropriate for the types of data collected. However, the autoimmune gastritis group was relatively small (24 patients), which limits how confidently we can apply findings to all autoimmune patients. The study was conducted at a single hospital in China, so results may not perfectly match other populations.
What the Results Show
The autoimmune gastritis group showed distinctly different characteristics compared to the H. pylori group. Autoimmune patients had significantly lower pepsinogen I levels (a marker of stomach acid-producing cells), with a median of 11.5 compared to 66.5 micrograms per liter in H. pylori patients. They also had much lower vitamin B12 levels (269 vs. 538 nanograms per liter), which makes sense because autoimmune gastritis damages the cells that help absorb B12. When doctors looked at the cancers under the endoscope, autoimmune patients more often had flat or slightly raised lesions (type 0-I or 0-II), while H. pylori patients more commonly had depressed lesions (type 0-IIa or 0-IIc). The autoimmune group had a higher rate of a specific type of cancer called signet ring cell carcinoma (30.8% vs. 7.0%), which is generally more aggressive.
The tissue damage patterns differed significantly between groups. H. pylori patients showed more extensive atrophy (shrinking of stomach tissue) and intestinal metaplasia (stomach lining cells changing to look like intestinal cells), with most falling into the most severe stages (stages 3 and 4) on both OLGA and OLGIM classification systems. Autoimmune patients had less extensive tissue damage overall. Hemoglobin levels were also lower in autoimmune patients (125 vs. 133 grams per liter), suggesting more chronic blood loss or nutritional deficiency. The endoscopic submucosal dissection treatment, a minimally invasive procedure to remove early cancers, was performed in both groups, but the study notes that different follow-up strategies may be needed based on these distinct patterns.
This research adds important detail to existing knowledge about stomach cancer development. H. pylori has long been recognized as a major risk factor for stomach cancer, and this study confirms that H. pylori-related cancers tend to develop in heavily damaged stomach tissue with extensive atrophy. Autoimmune gastritis is a less common cause of stomach cancer, and this study is among the first to systematically compare how cancers arising from autoimmune gastritis differ from H. pylori-related cancers. The finding that autoimmune patients have more signet ring cell carcinomas aligns with some previous research suggesting autoimmune gastritis may lead to more aggressive cancer types. The distinct appearance of lesions under endoscopy provides practical guidance for doctors performing screening.
The autoimmune gastritis group was much smaller (24 patients) than the H. pylori group (106 patients), which means findings about autoimmune patients are less statistically robust. The study was conducted at a single hospital in Beijing, so results may not apply equally to other geographic regions or populations with different genetic backgrounds. The study is observational, meaning researchers reviewed existing medical records rather than randomly assigning patients to different treatments, so we cannot prove that the inflammation type directly causes the different cancer patterns. The study does not include long-term follow-up data, so we cannot determine whether the different monitoring strategies actually lead to better outcomes for patients.
The Bottom Line
If you have been diagnosed with chronic stomach inflammation, ask your doctor whether it is caused by H. pylori infection or autoimmune gastritis, as this affects your cancer risk profile and screening needs. H. pylori patients should follow standard screening guidelines, which typically include regular endoscopy and treatment of the infection. Autoimmune gastritis patients may need more frequent monitoring given the different appearance of early cancers and the higher rate of aggressive cancer types. Maintain adequate vitamin B12 levels through supplementation if you have autoimmune gastritis, as this study shows these patients have significantly lower B12. These recommendations are based on moderate evidence from a single-center study and should be discussed with your gastroenterologist.
This research is most relevant to patients with diagnosed chronic stomach inflammation, particularly those with autoimmune gastritis who may have been receiving the same monitoring as H. pylori patients. Gastroenterologists and primary care doctors should consider these findings when developing screening plans. Patients with a family history of stomach cancer or those living in regions with high stomach cancer rates should be especially attentive. This research is less immediately relevant to people without stomach inflammation or those with other types of gastritis.
Early cancers caught through endoscopic screening can often be treated successfully with minimally invasive procedures, potentially within weeks to months. However, the benefit of different monitoring strategies depends on catching cancers at early stages, which requires consistent follow-up over years. You should not expect to see immediate health changes from this research, but rather use it to inform long-term screening decisions with your doctor. If you have autoimmune gastritis, implementing more frequent monitoring now could prevent problems years in the future.
Frequently Asked Questions
What is the difference between H. pylori gastritis and autoimmune gastritis?
H. pylori gastritis is caused by a bacterial infection that damages the stomach lining, while autoimmune gastritis occurs when your immune system mistakenly attacks your own stomach cells. They produce different patterns of tissue damage and different types of early cancers, requiring different monitoring approaches.
Do autoimmune gastritis patients have higher stomach cancer risk than H. pylori patients?
Both conditions increase stomach cancer risk, but in different ways. Autoimmune gastritis patients develop more aggressive cancer types (signet ring cell carcinoma in 30.8% of cases vs. 7.0% in H. pylori patients) but with less extensive tissue damage overall. This means autoimmune patients need different screening strategies, not necessarily more frequent screening.
Why do autoimmune gastritis patients have low vitamin B12 levels?
Autoimmune gastritis damages the stomach cells that produce intrinsic factor, a protein needed to absorb vitamin B12 from food. This study found autoimmune patients had B12 levels of 269 nanograms per liter versus 538 in H. pylori patients, making supplementation important for autoimmune patients.
How often should I get screened for stomach cancer if I have autoimmune gastritis?
This study suggests autoimmune and H. pylori patients need different screening schedules, but the exact frequency should be determined by your gastroenterologist based on your individual risk factors. Discuss this research with your doctor to develop a personalized monitoring plan.
Can endoscopic submucosal dissection treat early stomach cancer from autoimmune gastritis?
Yes, this minimally invasive procedure can remove early cancers in both H. pylori and autoimmune gastritis patients. However, the different appearance of autoimmune-related cancers means doctors need to know what to look for to identify them during endoscopy.
Want to Apply This Research?
- If you have autoimmune gastritis, track your endoscopy appointment dates and results in a health app. Set reminders for vitamin B12 level checks every 6 to 12 months, and log your B12 supplementation doses. Record any symptoms like abdominal pain, nausea, or changes in appetite, as these may warrant earlier screening.
- Create a calendar reminder for your next endoscopy appointment based on your doctor’s recommendation. If you have autoimmune gastritis, ask your doctor about B12 supplementation and add it to your daily medication tracker. Set a reminder to discuss screening frequency at your next gastroenterology visit, bringing this research to show your doctor.
- Use your health app to maintain a timeline of all endoscopy procedures and their results. Track vitamin B12 and pepsinogen I blood test results when available. If you have autoimmune gastritis, log any symptoms between appointments and note whether they change. Share this information with your gastroenterologist at each visit to help adjust your monitoring plan based on your individual risk profile.
This research compares characteristics of early stomach cancer in two different types of chronic gastritis but does not establish definitive treatment protocols. The findings are based on a single-center study with a small autoimmune gastritis group, limiting generalizability. If you have been diagnosed with chronic stomach inflammation or autoimmune gastritis, consult your gastroenterologist about appropriate screening and monitoring strategies tailored to your specific condition. Do not use this information to self-diagnose or delay medical evaluation. This article is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.